Several structural indexes based on the FTIR results were defined to evaluate the aging extent of the binders.
The following factors were examined as a product of an interaction between "sex and gender" that could not be studied in isolation: aging, extent of comorbidity, Body Mass Index (BMI), smoking, severity of bony and soft tissue pathology, incidence of work-related injuries, and pain perception that affects active range of motion.
Probability of cure varies according to patient's age, extent of disease and tumor biology (Maris et al., 2007 [1]; Brodeur, 2003 [2]; Cohn et al., 2009 [3]).
In 2005, data from 8,800 neuroblastoma patients were analyzed to develop a comprehensive classification system based on age, extent of disease (or stage), MYCN status, and several other biological and genetic factors.
While the prognosis has traditionally been based on conventional histopathology and clinical staging (based on age, extent of resection, and presence or absence of metastasis), it has become apparent in recent years that the inherent biology of the tumor plays a significant part in predicting survival and sometimes supersedes clinical or pathologic risk factors.
Patients were matched according to histological grade, age, extent of tumor removal, and tumor location.
All of the other variables (age, extent of disease, grade, receptor status) were similarly distributed in the two arms.
The most predictive variable was Gleason score, followed by baseline PSA, age, extent of disease, and clinical stage.
This association could not be explained by or adjusted for age, extent of disease or pregnancy hormones.
Several prognostic factors have been proposed: age, extent of resection, and KPS, and also some molecular markers [ 4– 6].
bHazard ratio adjusted for cancer type, gender, age, extent of cancer, acute and chronic comorbidities, and hospital level.
